GRIGGIO, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 3.135
EU - Europa 1.642
AS - Asia 960
AF - Africa 44
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
SA - Sud America 7
Totale 5.807
Nazione #
US - Stati Uniti d'America 3.105
CN - Cina 501
IT - Italia 355
SG - Singapore 288
SE - Svezia 232
IE - Irlanda 211
AT - Austria 155
UA - Ucraina 133
DE - Germania 117
FR - Francia 115
FI - Finlandia 94
DK - Danimarca 52
IN - India 35
PL - Polonia 34
KR - Corea 33
SN - Senegal 31
GB - Regno Unito 30
CA - Canada 29
VN - Vietnam 27
BY - Bielorussia 22
HK - Hong Kong 22
NL - Olanda 20
ID - Indonesia 18
RU - Federazione Russa 18
BE - Belgio 16
CH - Svizzera 13
ES - Italia 10
EU - Europa 10
UZ - Uzbekistan 10
AU - Australia 9
JP - Giappone 6
ZA - Sudafrica 6
AR - Argentina 4
GR - Grecia 4
IR - Iran 4
RO - Romania 4
TH - Thailandia 4
TW - Taiwan 4
CZ - Repubblica Ceca 2
EG - Egitto 2
NG - Nigeria 2
PH - Filippine 2
PK - Pakistan 2
TR - Turchia 2
BW - Botswana 1
CI - Costa d'Avorio 1
CO - Colombia 1
HU - Ungheria 1
IL - Israele 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
MX - Messico 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
TG - Togo 1
UY - Uruguay 1
Totale 5.807
Città #
Chandler 546
Santa Clara 306
Beijing 301
Singapore 230
Dublin 210
Ashburn 155
Vienna 155
Ann Arbor 154
Nyköping 115
Jacksonville 110
Dearborn 104
Fairfield 102
Torino 93
Houston 80
Wilmington 73
Medford 71
Princeton 62
Columbus 61
Woodbridge 59
Fremont 53
Villeurbanne 52
San Mateo 50
Seattle 48
Florence 38
Helsinki 33
Turin 32
Redwood City 31
Guangzhou 28
Washington 28
Warsaw 26
Cambridge 25
Dong Ket 18
Jakarta 18
Pisa 18
Munich 17
New York 17
Toronto 16
Brussels 15
Hangzhou 15
Hefei 15
Chennai 12
Nanjing 12
Boston 11
Chengdu 11
Milan 11
Boardman 10
Düsseldorf 10
Los Angeles 10
Norwalk 10
Hong Kong 9
Linden 9
Rotterdam 9
Oerlikon 8
Paris 8
Shanghai 8
Codogno 7
Falls Church 7
Phoenix 7
Piemonte 7
Provo 7
San Diego 7
Central District 6
Guiyang 6
Ottawa 6
Rome 6
San Jose 6
Wayne 6
Casorzo 5
Changsha 5
Kunming 5
Liverpool 5
Seoul 5
Volpago Del Montello 5
Bologna 4
Canelli 4
Erlangen 4
Falkenstein 4
Leawood 4
Mortara 4
Nanchang 4
Pune 4
Shenyang 4
Upper Marlboro 4
Wuhan 4
Adelaide 3
Balingen 3
Cape Town 3
Changchun 3
Dallas 3
Des Moines 3
Grugliasco 3
Heidelberg 3
Jaipur 3
Jinan 3
Johannesburg 3
Limoges 3
Philadelphia 3
San Francesco 3
Swindon 3
Taipei 3
Totale 3.928
Nome #
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 292
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 286
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 203
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 195
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 162
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 149
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 147
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 145
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 133
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 132
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 117
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance 115
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 113
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 110
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 109
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs 109
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 108
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 108
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 106
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 105
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 105
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 104
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE 99
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 98
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 94
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 92
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 92
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 91
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 88
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 87
The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection 84
The Hypoxia-Inducible Factor-1 alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance 81
TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 81
null 80
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells 79
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 79
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll 79
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells 78
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs 77
The association of dexamethasone + simvastatin to overcome environment-mediated chemoresistance of chronic lymphocytic leukemia (CLL) cells 75
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells 75
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THEIDENTIFICATION OF NOVEL TUMOR-ASSOCIATED ANTIGENS INCHRONIC LYMPHOCYTIC LEUKEMIA 74
Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib 74
IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS 73
Cd200 baseline serum levels predict prognosis of chronic lymphocytic leukemia 73
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 71
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 70
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE 70
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 67
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia 63
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 63
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia 61
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 56
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges 52
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells 49
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 47
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 46
The mevalonate pathway as a metabolic target to circumvent multidrug-resistance in chronic lymphocytic leukemia cells (CLL) 42
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia 30
CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? 26
MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells 20
Totale 5.985
Categoria #
all - tutte 18.083
article - articoli 0
book - libri 0
conference - conferenze 12.371
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.454


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020508 0 0 0 0 0 107 80 42 49 91 58 81
2020/2021776 73 70 34 41 126 39 44 70 59 33 105 82
2021/2022891 34 10 32 53 57 17 109 52 19 100 258 150
2022/20231.245 127 139 37 152 106 294 72 73 121 45 48 31
2023/2024510 63 97 41 24 21 105 10 51 5 22 20 51
2024/2025836 8 37 76 148 472 95 0 0 0 0 0 0
Totale 5.985